BioCentury | Jul 5, 2010
Company News

Bio3 Research, Protelica deal

...cardiovascular diseases, including arterial stenosis, restenosis and atherosclerotic plaque. Bio3 also received non-exclusive rights to Protelica's...
...and commercialize the compounds. Financial terms were not disclosed. Bio3 Research s.r.l. , Milan, Italy Protelica...
BioCentury | Apr 15, 2010
Targets & Mechanisms

Inhibiting inflammation in epilepsy

...fragments (including BoxA) that bind and antagonize HMGB1 to treat cardiovascular disorders. Bio3 and partner Protelica...
...Francesco Paolo Pilato told SciBX that based on the Nature Medicine findings, "Bio3 Research and Protelica...
...Milan, Italy New York University , New York, N.Y. NovImmune S.A. , Geneva, Switzerland Protelica...
Items per page:
1 - 2 of 2
BioCentury | Jul 5, 2010
Company News

Bio3 Research, Protelica deal

...cardiovascular diseases, including arterial stenosis, restenosis and atherosclerotic plaque. Bio3 also received non-exclusive rights to Protelica's...
...and commercialize the compounds. Financial terms were not disclosed. Bio3 Research s.r.l. , Milan, Italy Protelica...
BioCentury | Apr 15, 2010
Targets & Mechanisms

Inhibiting inflammation in epilepsy

...fragments (including BoxA) that bind and antagonize HMGB1 to treat cardiovascular disorders. Bio3 and partner Protelica...
...Francesco Paolo Pilato told SciBX that based on the Nature Medicine findings, "Bio3 Research and Protelica...
...Milan, Italy New York University , New York, N.Y. NovImmune S.A. , Geneva, Switzerland Protelica...
Items per page:
1 - 2 of 2